The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220- specific antibody reactivities in the sera of patients with different EBV- associated diseases

International Journal of Cancer

Volumn 79, Issue 5, 1998, Pages 481-486

  Xu, Jingwu ^a   Ahmad, Ali ^a   Blagdon, Marie ^a   D'Addario, Mario ^a   Jones, James F ^b   Dolcetti, Riccardo ^c   Vaccher, Emanuela ^c   Prasad, U ^d   Menezes, José ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c Ctro Riferimento Oncologico Aviano   (Italy)

^d UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ENVELOPE PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; INFECTIOUS MONONUCLEOSIS; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; VIRUS INFECTION;

ANTIBODIES, VIRAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TUMOR VIRUS INFECTIONS; VIRAL MATRIX PROTEINS;

EID: 0031719504     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981023)79:5<481::AID-IJC6>3.0.CO;2-X     Document Type: Article

References (38)

1. AHMAD, A. and MENEZES, T., Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J, 10, 258-266 (1996).
2. DAWSON-SAUNDERS, E.K. and TRAPP, R.G., Correlation and regression. In: Basic Clinical Biostatistics. Pp. 162-146. Appleton and Lange, Norwalk, CT (1990).
3. DE SCHRYVER, A., KLEIN, G., HEWESTON, J., ROCCHI, G., HENLE, W., HENLE, G., Moss, D.J. and POPE, J.H., Comparison of neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA). Int. J. Cancer, 13, 353-362 (1974).
4. EPSTEIN, M.A., ACHONG, B.G., BARR, Y.M., ZAJAC, B., HENLE, G. and HENLE, W., Morphological and virological investigation of cultured Burkitt tumor lymphoblasts (strain Raji). J. nat. Cancer Inst., 37, 547-559 (1966).
5. EPSTEIN, M.A., MORGAN, A.J., FINERTY, S., RANDLE, B.J. and KIRKWOOD, J.K., Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature, 318, 287-289 (1985).
6. GRUSS, H.J., PINTO, A., DUYSTER, J., POPPEMA, S. and HERRMANN, F., Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol. Today, 18, 156-163 (1997).
7. HENLE, G., HENLE, W. and DIEHL, V., Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc. nat. Acad. Sci. (Wash.), 59, 94-101 (1968).
8. HOFFMAN, G.J., LAZAROWITZ, S.G. and HAYWARD, S.D., Monoclonal antibody against a 250,000 dalton glycoprptein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. nat. Acad. Sci. (Wash.), 77, 2979-2983 (1980).
9. HOWELL, D.M., ANDREOTTI, P.E., DAWSON, J.R. and CRESSWELL, P., Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J. Immunol, 134, 971-979 (1985).
10. KAGNOFF, M.F., Mucosal immunology: new frontiers. Immunol. Today, 17, 57-61 (1996).
11. KANAVAROS, P., BRIERE, J., LESCS, M.C. and GAULARD, P., Epstein-Barr virus in non-Hodgkin's lymphomas of the upper respiratory tract: association with sinonasal localization and expression of NK and/or T cell antigens by tumor cells. J. Pathol., 178, 297-302 (1996).
12. KHANNA, R., BURROWS, S.R. and Moss, D.J., Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev., 59, 387-405 (1995).
13. KHYATTL, M., PATEL, P.C., STEFANESCU, I. and MENEZES, J., Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as target antigen for EBV-specific antibody-dependent cellular cytotoxicity. J. Virol., 65, 996-1001 (1991).
14. KHYATTI, M., STEFANESCU, I., BLAGDON, M. and MENEZES, J., Epstein-Barr virus gp350-specific antibody titres and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets. J. Infect. Dis., 170, 1439-1447 (1994).
15. MANCIULEA, M., PRICOP, L., SULICA, A. and HEBERMAN, R.B., Inhibition of human natural kilJer cell activity by polyclonal IgM. Mol. Immunol., 26, 1087-1094 (1989).
16. MAYER, J., SCHWARZMANN, F., REISH, I. and WOLF, H., Pathobiology of Epstein-Barr virus and related diseases. Biotest Bull., 5, 3-12 (1993).
17. MEGGETTO, F., BROUSSET, P., SELVES, J., DELSOL, G. and MARIAME, B., Reed-Sternberg cells and "bystander" lymphocytes in lymph nodes affected by Hodgkin's disease are infected with different strains of Epstein-Barr virus. J. Virol., 71, 2547-2549 (1997).
18. MENEZES, J., JONDAL, M., LEIBOLD, W. and DORVAL, G., Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of EBV-associated nuclear antigen (EBNA) and lymphocyte transformation. Infect. Immunol., 13, 303-310 (1976).
19. MILLER, G., ROBINSON, J., HESTON, L. and LIPMAN, M., Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection and interference. Proc. nat. Acad. Sci. (Wash.), 71, 4006-4010
20. MORGAN, A.J., Epstein-Bar virus vaccines. Vaccine, 10, 563-571 (1992).
21. NEMEROW, G.R., WOLFERT, R., MCNAUGHTON, M.E. and COOPER, N.R., Identification and characterization of the EBV receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J. Virol., 55, 347-351 (1985).
22. NOMORI, H., KAMEYA, T., SHIMOSATO, Y., SAITO, H., EBIHARA, S. and ONO, I., Nasopharyngeal carcinoma: immunohistochemical study for keratin, secretory component and leukocyte common antigen. Jpn. J. clin. Oncol., 15, 95-105 (1985).
23. OKANO, M., MATSUMOTO, S., OSATO, T., SAKIYAMA, Y., THIELE, G. M. and PURTILO, D. T. Severe chronic active Epstein-Barr virus infection syndrome. Clin. Microbiol. Rev.,4, 129-135 (1991).
24. OKANO, M., THIELE, G.M., DAVIS, J.R., GRIERSON, H.L. and PURTILO, D.T., Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin. Microbiol. Rev., 1, 300-312 (1988).
25. ORTALDO, J.R., MASON, A.T. and O'SHEA, J.J., Receptor-induced death in human natural killer cells: involvement of CD16. J. exp. Med., 181, 339-344 (1995).
26. PEARSON, G.R. and ORR, T,W. Antibody-dependent cellular cytotoxicity against cells expressing Epstein-Barr virus antigens. J. nat. Cancer Inst., 56, 485-488 (1976).
27. PEARSON,G.R. and QUALTIERE, L.F., Papain solubilization of the Epstein-Barr virus-induced membrane antigen. J. Virol., 28, 344-351 (1978).
28. PI, G.H., ZENG, Y. and WOLF, H., Detection of IgA antibody to EBV membrane antigen using Staphylococcus aureus preabsorbed sera is closely associated with nasopharyngeal carcinoma. J. Virol. Methods, 15, 33-39 (1987).
29. POPE, J.H., HORNE, M.K. and SCOTT, W., Transformation of foetal human leukocytes in vitro by filterates of a human leukemic cell line containing herpes-like virus. Int. J. Cancer, 3, 857-866 (1968).
30. PURTILO, D.T. Hypothesis, pathogenesis and phenotypes of an X-linked recessive lymphoproliferative response. Lancet, 1, 320-322 (1976).
31. rd ed.). pp. 2397-2446. Lippincott-Raven. Philadelphia (1996).
32. SIXBEY, J.W. and YAO, Q.Y., Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science, 255, 1578-1580 (1992).
33. TANNER, J., WEIS, J., FEARON, D., WHANG, V. and KIEFF, E., Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis. Cell, 50, 203-213 (1987).
34. TANNER, J.E., WEI, M.X., ALFIERI, C., AHMAD, A., TAYLOR, P., OOKA, T. and MENEZES, J., Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders. J. Infect. Dis., 175, 38-46 (1997).
35. THORLEY-LAWSON, D.A. and GEILINGER, K., Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc. nat. Acad. Sci. (Wash.), 77, 5307-5311 (1980).
36. VOLTARELLI, J.C., GJERSET, G. and ANASETTI, C., Adhesion of CD16-positive K cells to antibody-coated targets is mediated by CD2 and CD18 receptors. Immunology 79, 509-511 (1993).
37. YAO, Q.Y., ROWE, M., MORGAN, A.J., SAM, C.K., PRASAD, U., DANG, H., ZENG, Y. and RICKINSON,A.B., Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: Incidence and potential for virus neutralization. Mr. J. Cancer, 48, 45-50 (1991).
38. ZHOU, X.G., HAMILTON-DUTOIT, S.J., YAN, Q.H. and PALLESEN, G., High frequency of Epstein-Barr virus in Chinese peripheral T cell lymphoma. Histopathology, 24, 115-122 (1994).